1448355-15-4
Chemical Structure
HL23
- CAS No.: 1448355-15-4
- Formula:C44H44N2O7
- Molecular Weight:712.83
InChIKey: QHIZVNHVLKMCBJ-PXLJZGITSA-N
SMILES: CN([C@@]1([H])CC2=CC=C(OC)C(OC3=CC=C(C[C@]4([H])N(C)CC5)C=C3)=C2)CCC6=C1C(OC7=C(OC)C=C5C4=C7)=C(OC(C8=CC=CC=C8)=O)C(OC)=C6
Biological Activity: HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HL23 | 99.64% | HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
